SITC

Zymeworks Announces Appointment of Dr. Alessandra Cesano to its Board of Directors

Retrieved on: 
Thursday, February 8, 2024
Standard of care, Immunotherapy, Amgen, Prostate cancer, Research, SITC, Society, Patient, ESSA, FDA, Publication, Biomarker, Doctor of Philosophy, NanoString Technologies, Therapy, Drug development, Biogen, Journal, University, Puma Biotechnology

Dr. Cesano succeeds Dr. Kenneth Hillan, who will step down effective today after a successful 7-year tenure as a director of Zymeworks.

Key Points: 
  • Dr. Cesano succeeds Dr. Kenneth Hillan, who will step down effective today after a successful 7-year tenure as a director of Zymeworks.
  • “Zymeworks is honored to welcome Dr. Cesano to our board of directors,” said Kenneth Galbraith, Chair and Chief Executive Officer of Zymeworks.
  • She joins three other new directors appointed in 2023: Mr. Derek Miller, Mr. Carlos Campoy, and Dr. Nancy Davidson.”
    “The Zymeworks board of directors is sincerely grateful to Dr. Hillan for his dedicated service and significant contributions to the board.
  • Dr. Cesano was also appointed to serve as a member of the research and development committee and nominating and corporate governance committee of the board of directors.

23andMe Reports Third Quarter Fiscal 2024 Financial Results

Retrieved on: 
Wednesday, February 7, 2024
GSK plc, PGS, Pharmacokinetics, SAN, Growth, Net, Inflammation, Table, Investigational New Drug, Research, SITC, Genetics, NK, Society, Consumer, Patient, IND, African Americans, FDA, Database, Immunotherapy, Therapy, Total, Premium, Webcast, Cancer, 23andMe, GSK, Workforce, Pharmaceutical industry

SOUTH SAN FRANCISCO, Calif., Feb. 07, 2024 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME), a leading human genetics and biopharmaceutical company, reported its financial results for the third quarter of fiscal year 2024 (FY24), which ended December 31, 2023.

Key Points: 
  • SOUTH SAN FRANCISCO, Calif., Feb. 07, 2024 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME), a leading human genetics and biopharmaceutical company, reported its financial results for the third quarter of fiscal year 2024 (FY24), which ended December 31, 2023.
  • “The Company had a very productive third quarter, with meaningful strategic progress across all three business lines,” said Anne Wojcicki, Co-Founder & CEO of 23andMe.
  • Full year Adjusted EBITDA deficit is adjusted to be in the range of $185 to $180 million for fiscal year 2024.
  • 23andMe will host a conference call at 4:30 p.m. Eastern Time today, February 7, 2024, to discuss the financial results for Q3 FY2024 and report on business progress.

Breaking Ground in Prostate Cancer: BriaCell Announces Lead Prostate Cancer Candidate Bria-Pros+, Initiates GMP Manufacturing

Retrieved on: 
Tuesday, February 6, 2024
Prostate cancer, Investigational New Drug, Cytokine, Immunotherapy, SITC, Clinical trial, NK, Society, Patient, IND, Good, Death, TSX, Allele, NKT, Therapy, Vaccine, Good manufacturing practice, HLA, Cancer, GMP, BCT

We are enthusiastic about commencing GMP manufacturing for our prostate cancer clinical candidate, continuing our efforts at transforming targeted cancer therapy via the introduction of potent personalized cellular cancer vaccines,” stated Dr. William V. Williams, BriaCell’s President and CEO.

Key Points: 
  • We are enthusiastic about commencing GMP manufacturing for our prostate cancer clinical candidate, continuing our efforts at transforming targeted cancer therapy via the introduction of potent personalized cellular cancer vaccines,” stated Dr. William V. Williams, BriaCell’s President and CEO.
  • “The successful development of this first candidate showcases our capacity to create novel cancer immunotherapies and advance them towards clinical application.
  • BriaCell genetically engineers cancer cell lines to produce cytokines and co-stimulatory factors that significantly increase immune stimulation compared to the unmodified (parent) cancer cell lines.
  • According to 2024 Cancer Facts & Figures , prostate cancer is projected to be the most common cancer among men in 2024.

Candel Therapeutics Sets Path to Success: Recent Achievements Pave the Way for a Promising 2024 Propelled by Key Value Drivers and Catalysts

Retrieved on: 
Monday, February 5, 2024
Injection, Serology, OS, Tumor microenvironment, Survival, Prostate cancer, Breast cancer, Immunotherapy, Pancreatic cancer, MD, PDAC, SITC, Enlightenment, Food and Drug Administration, Lung cancer, Society, Clinical trial, Therapy, Patient, Brain, Cancer, FDA, Biomarker, Trial of the century, Food, CADL, Fast track (FDA), CSO, Disease, Biology, Pancreatitis, Doctor of Philosophy, Valaciclovir, Conference, Pharmaceutical industry

“Candel is focused on delivering key value drivers to maximize the impact of its assets and to create substantial value to patients and other stakeholders.

Key Points: 
  • “Candel is focused on delivering key value drivers to maximize the impact of its assets and to create substantial value to patients and other stakeholders.
  • In 2023, we received Fast Track Designation from the FDA for CAN-2409, our most advanced product candidate, for both NSCLC and pancreatic cancer.
  • This platform is open for collaborations with external partners.”
    The Company's strategic prioritization of programs highlights Candel Therapeutics' commitment to operational excellence and efficiency.
  • This approach positions the Company for sustained success in the current dynamic market for new cancer therapeutics.

Elephas Announces $55 Million in Series C Funding

Retrieved on: 
Tuesday, January 23, 2024
Tao, Patient, SITC, Society, XMS Capital Partners, Cancer, Immunotherapy, Drug development, Biomarker

MADISON, Wis., Jan. 23, 2024 /PRNewswire/ -- Elephas Biosciences Corporation (Elephas), a private company, announced today that it has raised $55 million in Series C funding. Venture Investors Health Fund and State of Wisconsin Investment Board (SWIB) led the round. Continuing investments were made by Northpond Ventures, ARCH Ventures, Sands Capital, Moore Strategic Ventures, Tao Invest, and WARF Ventures. With this $55 million Series C funding, this brings the total raised by Elephas to $116.5 million.

Key Points: 
  • MADISON, Wis., Jan. 23, 2024 /PRNewswire/ -- Elephas Biosciences Corporation (Elephas), a private company, announced today that it has raised $55 million in Series C funding.
  • With this $55 million Series C funding, this brings the total raised by Elephas to $116.5 million.
  • Elephas is developing an oncology imaging diagnostics platform to predict response to immunotherapy using the latest advances in metabolic imaging.
  • "We remain intensely focused on our mission to improve care for cancer patients," stated Maneesh Arora, founder and CEO of Elephas.

ClearNote Health Announces New Proprietary Approach for Predicting Immunotherapy Treatment Response in Non-Small Cell Lung Cancer Using Only Blood

Retrieved on: 
Tuesday, January 16, 2024
Oncology, Health, Technology, Other Health, Artificial Intelligence, Biotechnology, Hope, Translational research, Translation, Prostate cancer, Patient, Biology, Research, SITC, DNA, Type 2 diabetes, PD-1, Nivolumab, Society, Cancer research, Nucleic acid thermodynamics, Immunotherapy, Risk, NSCLC, Plasma, Journal, Disease, Lung cancer, Biomarker, Pembrolizumab, Bayer, Pancreatic cancer, Pharmaceutical industry

The article, “ Plasma Cell-Free DNA Hydroxymethylation Profiling Reveals Anti-PD-1 Treatment Response and Resistance Biology in Non-Small Cell Lung Cancer ,” was published in the online issue of The Journal for ImmunoTherapy of Cancer, the official journal of the Society for Immunotherapy of Cancer (SITC) .

Key Points: 
  • The article, “ Plasma Cell-Free DNA Hydroxymethylation Profiling Reveals Anti-PD-1 Treatment Response and Resistance Biology in Non-Small Cell Lung Cancer ,” was published in the online issue of The Journal for ImmunoTherapy of Cancer, the official journal of the Society for Immunotherapy of Cancer (SITC) .
  • The comparison of plasma-derived cfDNA 5-hmC profiles revealed differences that distinguish patients responding to therapy from those not responding before and throughout treatment.
  • This underscores the value of 5hmC analysis for the measurement of treatment response biomarkers without the need for an invasive and potentially deadly tissue biopsy.
  • A recently published study in Cancer Research, “ The 5-Hydroxymethylcytosine Landscape of Prostate Cancer ,” showed the utility of ClearNote Health’s platform in marking epigenetic activation in prostate cancer and identifying hallmarks of prostate cancer progression.

Corbus Pharmaceuticals Announces FDA Clearance of IND Application for its anti-αvβ8 monoclonal antibody (CRB-601)

Retrieved on: 
Tuesday, January 9, 2024
Tumor microenvironment, Immunotherapy, Food, Society, SITC, Neoplasm, FDA, Pharmaceutical industry

Pre-clinical data presented at the 38th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) demonstrates CRB-601 overcame tumor immune exclusion and enhanced the activity of immune checkpoint inhibitors in vivo.

Key Points: 
  • Pre-clinical data presented at the 38th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) demonstrates CRB-601 overcame tumor immune exclusion and enhanced the activity of immune checkpoint inhibitors in vivo.
  • The Company expects to enroll the first participant in a Phase 1 study in the first half of 2024.
  • “CRB-601 blocked latent TGFβ activation and enhanced immune cell penetration into the tumor microenvironment in pre-clinical models.
  • We believe this mechanism of action is complimentary to the effects of anti PD(L)-1 therapy leading to enhanced combinatorial efficacy.

Werewolf Therapeutics Provides Business Update and Highlights 2024 Strategic Outlook

Retrieved on: 
Monday, January 8, 2024
Report, Therapeutic index, Immunotherapy, Forecasting, IND, Inflammation, Therapy, Cancer, Society, Non-Hodgkin lymphoma, RDE, Patient, Finance, SITC, Pharmaceutical industry

WATERTOWN, Mass., Jan. 08, 2024 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the body’s immune system for the treatment of cancer, today provided a business update and outlined its strategic outlook and expected milestones for 2024.

Key Points: 
  • -  Prioritizing development of wholly owned clinical assets, WTX-124 and WTX-330; key updates from both INDUKINETM programs anticipated in 2024 -
    WATERTOWN, Mass., Jan. 08, 2024 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the body’s immune system for the treatment of cancer, today provided a business update and outlined its strategic outlook and expected milestones for 2024.
  • In 2024, Werewolf plans to report initial data from the Phase 1 clinical trial in the second quarter of 2024.
  • In 2024, Werewolf plans to:
    Present preclinical data from WTX-712 in the first half of 2024.
  • Present preclinical data demonstrating the potential of INDUKINE molecules for inflammatory diseases by the fourth quarter of 2024.

Molecular Partners Provides Updates at 42nd Annual J.P. Morgan Healthcare Conference

Retrieved on: 
Sunday, January 7, 2024
NAMD, Conference, Gene family, Partnership, Neoplasm, Tumor microenvironment, IND, Hematopoietic stem cell transplantation, Radionuclide, CD47, Data, Myelodysplastic syndrome, Macrophage, Molecular Partners, HSC, Society, CHF, Novartis, ASH, COVID-19, DARPin, Toxicity, RDT, CD16, Stem cell, HSCT, Patient, Acute myeloid leukemia, Safety, Therapy, AML, DLL3, Health, SITC, Pharmaceutical industry

53 LR Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics, today announced it will present a business overview and provide its 2024 outlook at the 42nd Annual J.P. Morgan Healthcare Conference.

Key Points: 
  • 53 LR Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics, today announced it will present a business overview and provide its 2024 outlook at the 42nd Annual J.P. Morgan Healthcare Conference.
  • Data were presented at the 65th American Society of Hematology (ASH) Annual Meeting and Exposition in December 2023.
  • Molecular Partners continues to progress its RDT platform and portfolio of projects, both in-house and in partnership with Novartis.
  • In addition to these updates, Novartis has returned the rights to the ensovibep program, previously under investigation for the treatment of COVID-19, to Molecular Partners.

Werewolf Therapeutics Appoints Michael Atkins, M.D., to its Board of Directors

Retrieved on: 
Thursday, January 4, 2024
Giant, Melanoma, Werewolf, Book, Immunotherapy, SITC, Kidney cancer, Society, Therapy, Biopharmaceutical, Georgetown University Medical Center, Harvard Medical School, Committee, Pharmaceutical industry

WATERTOWN, Mass., Jan. 04, 2024 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of novel, conditionally activated INDUKINE™ therapeutics engineered to stimulate the body’s immune system for the treatment of cancer, today announced the appointment of Michael B. Atkins, M.D., to its Board of Directors.

Key Points: 
  • WATERTOWN, Mass., Jan. 04, 2024 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of novel, conditionally activated INDUKINE™ therapeutics engineered to stimulate the body’s immune system for the treatment of cancer, today announced the appointment of Michael B. Atkins, M.D., to its Board of Directors.
  • “Mike is a world-renowned oncologist and clinical researcher who has made countless contributions to the field of cancer immunotherapy.
  • I am delighted to have Mike join our Board at this important time in the clinical development of our WTX-124 and WTX-330 INDUKINE molecules,” said Dan Hicklin, Ph.D., President and Chief Executive Officer of Werewolf Therapeutics.
  • He has published over 500 scientific and review articles, co-edited five books, and given over 800 lectures worldwide.